euro adhoc: Marseille-Kliniken AG
Board of Directors (Appointments and
Changes)
- Mr. Peter Paul Gardosch is a new member of the Marseille-Kliniken
AG Board
- Expansion in the field of acute clinics
-------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------
05.06.2008
Berlin, June 5, 2008. The Supervisory Board of the Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) has named Mr. Peter Paul Gardosch (49) as a new member of the Board of the Marseille-Kliniken AG effective August 1, 2008.
Mr. Peter Paul Gardosch will take over responsibility for the operative units of Acute Clinics and Rehabilitation. He will be helping increase the number of locations of acute clinics and, at the same time, taking the opportunity to take over shareholdings in acute clinics in the mid-range segment when larger competitors cannot hold shares in such clinics due to anti-trust regulations. The company is also planning to replace the coming revenue cuts from other fields by selling its unit for Rehabilitation. The Marseille-Kliniken AG is working to take over at least one acute clinic for basic and regulated care within one year.
The new member of the Board, Mr. Peter Paul Gardosch, brings along enormous expertise for his work in the field of acute clinics. He finished his studies in Human Medicine at the University of Hamburg and worked for many years as an emergency physician. After his studies, Mr. Gardosch started as an EMS physician for the German Army before joining the international Solvay Group in 1992 as Director of Clinical Research. In 1995, Mr. Gardosch was entrusted with advising hospitals for the celebrated firm of consultants Roland Berger and helped more than 50 medium-sized companies in industry and the trades. In 1999, he began building his own consulting company for companies active in the field of acute medicine. From 2003 to 2006, Mr. Gardosch worked as CEO of the Humaine Group responsible 10 acute clinics with 2,100 beds and sales of 230 mill. Euros. The company was later sold to the Helios Corporation. After this, from 2006 to 2008, Mr. Gardosch continued to work at his own consulting company.
The Marseille-Kliniken AG has already been working successfully for the past two years in the field of acute clinics at the St. Nikolas Hospital in Büren in connection with a care facility there. The St. Nikolaus Hospital is inteded to be a hospital specialising in geriatrics to meet the growing need for age-specific treatment while taking account of normal co-morbidity. Presently, a Medical Care Centre (MCC) is being set up to assure integrated care for patients.
End of ad hoc release
end of announcement euro adhoc --------------------------------------------------------------------------------
Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin
GERMANY
Tel.: +4930 / 246 32-400
Fax: +4930 / 246 32-401
www.marseille-kliniken.com
;
or
Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
GERMANY
Tel.: +4940 / 320 279 10
Fax: +4940 / 320 279 114
www.hillermann-consulting.de
Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hamburg / regulated dealing
Original content of: Marseille-Kliniken AG, transmitted by news aktuell